CRISPR/CAS9 - The ultimate weapon to battle infectious diseases?
Details
Publication Year 2016-11-16,Volume 19,Issue #2,Page doi: 10.1111/cmi.12693
Journal Title
Cellular Microbiology
Publication Type
Journal Article
Abstract
Infectious diseases are a leading cause of death worldwide. Novel therapeutics are urgently required to treat multi-drug resistant organisms such as Mycobacterium tuberculosis (Mtb) and to mitigate morbidity and mortality caused by acute infections such as malaria and dengue fever virus as well as chronic infections such as human immunodeficiency virus -1 (HIV-1) and hepatitis B virus (HBV). The CRISPR/Cas9 system, which has revolutionized biomedical research, holds great promise for the identification and validation of novel drug targets. Since its discovery as an adaptive immune system in prokaryotes, the CRISPR/Cas9 system has been developed into a multi-faceted genetic modification tool, which can now be used to induce gene deletions or specific gene insertions, such as conditional alleles or endogenous reporters in virtually any organism. The generation of CRISPR/Cas9 libraries that can be used to perform phenotypic whole genome screens, provides an important new tool that will aid in the identification of critical host factors involved in the pathogenesis of infectious diseases. In this review, we will discuss the development and recent applications of the CRISPR/Cas9 system used to identify novel regulators, which might become important in the fight against infectious diseases. This article is protected by copyright. All rights reserved.
Publisher
Wiley
Research Division(s)
Molecular Genetics Of Cancer; Infection And Immunity
PubMed ID
27860197
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2016-11-24 03:36:55
Last Modified: 2018-07-05 03:47:24
An error has occurred. This application may no longer respond until reloaded. Reload 🗙